禮來公司與總部位於香港的人工智慧藥物研發公司Insilico Medicine達成一項價值高達27.5億美元的合作協議，旨在利用人工智慧進行臨床前藥物研發。根據協議，禮來公司將獲得一種用於治療糖尿病的口服GLP-1藥物以及其他候選藥物的獨家權益，這標誌著禮來公司在人工智慧驅動的代謝疾病研發領域取得了巨大進展。
CNBC +3
禮來-Insilico合作協議關鍵細節（2026年3月）交易結構：一項全球許可和研究合作，Insilico將提供臨床前候選藥物。
財務條款：包括向Insilico支付1.15億美元的首付款，以及潛在的里程碑付款和特許權使用費，總額最高可達27.5億美元。
重點領域：該協議具體涵蓋一種利用Insilico專有的生成式人工智慧平台開發的用於治療糖尿病的口服GLP-1候選藥物。
提升效率：此次合作凸顯了禮來公司利用人工智慧加速研發並提高新藥發現效率的策略。路透社 +3
此舉順應了製藥公司與香港和中國生物技術公司進行大規模合作的趨勢，這些合作專注於將下一代人工智慧應用於藥物研發。
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
AI Overview
Eli Lilly is partnering with Hong Kong-based AI drug developer Insilico Medicine in a deal worth up to $2.75 billion, aimed at leveraging AI for preclinical drug discovery. Under the agreement, Eli Lilly acquires exclusive rights to an oral GLP-1 drug for diabetes, plus additional candidates, showcasing a massive expansion in AI-driven metabolic disease R&D.
CNBC +3Key Details of the Eli Lilly-Insilico Deal (March 2026)Deal Structure: A global licensing and research collaboration where Insilico provides preclinical candidates.
Financial Terms: Includes a $115 million upfront payment for Insilico, with potential milestone payments and royalties reaching up to $2.75 billion.
Focus Areas: The deal specifically covers an orally available GLP-1 drug candidate developed using Insilico's proprietary generative AI platform for diabetes.
Targeting Efficiency: This partnership highlights Eli Lilly's strategy to use AI to speed up R&D and improve the efficiency of discovering new medicines.
Reuters +3
This move follows a trend of massive pharmaceutical collaborations with Hong Kong and Chinese biotechnology firms focusing on next-generation artificial intelligence in drug development.
Facebook +2
This move follows a trend of massive pharmaceutical collaborations with Hong Kong and Chinese biotechnology firms focusing on next-generation artificial intelligence in drug development.
Facebook +2
沒有留言:
張貼留言